drugset / Trial / NCT03635450
Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE
Phase 1
Completed
6 enrolled
Joanne Kurtzberg, MD
Duke Clinical and Translational Science Institute (CTSI), part of the NIH Clinical and Translational Science Awards (CTSA) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To determine the safety of single and repeated intravenous doses of hCT-MSC in newborn infants with HIE.
Timeline
- Start
- 2018-12-27
- Primary completion
- 2019-07-28
- Completion
- 2020-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hCT-MSC | Cell therapy | — | Intravenous |